门静脉高压的病理生理学及其临床关联。
Pathophysiology of portal hypertension and its clinical links.
作者信息
Seo Yeon Seok, Shah Vijay H
机构信息
Gastroenterology Research Unit, Mayo Clinic, Rochester, MN - 55905, USA.
Gastroenterology Research Unit, Mayo Clinic, Rochester, MN - 55905, USA ; Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN - 55905, USA.
出版信息
J Clin Exp Hepatol. 2011 Sep;1(2):87-93. doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.
Abstract
Portal hypertension is a major cause of morbidity and mortality in patients with liver cirrhosis. Intrahepatic vascular resistance due to architectural distortion and intrahepatic vasoconstriction, increased portal blood flow due to splanchnic vasodilatation, and development of collateral circulation have been considered as major factors for the development of portal hypertension. Recently, sinusoidal remodeling and angiogenesis have been focused as potential etiologic factors and various researchers have tried to improve portal hypertension by modulating these new targets. This article reviews potential new treatments in the context of portal hypertension pathophysiology concepts.
摘要
门静脉高压是肝硬化患者发病和死亡的主要原因。肝内结构扭曲和肝内血管收缩导致的肝内血管阻力增加、内脏血管扩张引起的门静脉血流增加以及侧支循环的形成被认为是门静脉高压发生的主要因素。最近，窦状隙重塑和血管生成已成为潜在的病因因素受到关注，并且各种研究人员试图通过调节这些新靶点来改善门静脉高压。本文在门静脉高压病理生理学概念的背景下综述了潜在的新治疗方法。
相似文献
1
Pathophysiology of portal hypertension and its clinical links.
J Clin Exp Hepatol. 2011 Sep;1(2):87-93. doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.
2
Pathophysiology and a Rational Basis of Therapy.
Dig Dis. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6.
3
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
4
Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
Gastroenterology. 2013 Oct;145(4):874-884.e5. doi: 10.1053/j.gastro.2013.06.036. Epub 2013 Jun 22.
5
The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Biosci Rep. 2017 Dec 15;37(6). doi: 10.1042/BSR20171015. Print 2017 Dec 22.
6
Pathophysiology of portal hypertension.
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8.
7
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
8
Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats.
Clin Sci (Lond). 2017 Jan 1;131(1):69-86. doi: 10.1042/CS20160470. Epub 2016 Nov 1.
9
Pharmacologic prevention of variceal bleeding and rebleeding.
Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5.
10
Cellular and molecular basis of portal hypertension.
Clin Liver Dis. 2001 Aug;5(3):629-44. doi: 10.1016/s1089-3261(05)70185-9.
引用本文的文献
1
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.
Front Cardiovasc Med. 2024 Oct 1;11:1469492. doi: 10.3389/fcvm.2024.1469492. eCollection 2024.
2
Improved Applicability and Diagnostic Accuracy of the Novel Spleen-Dedicated Transient Elastography Device for High-Risk Esophageal Varices.
Diagnostics (Basel). 2024 Mar 30;14(7):743. doi: 10.3390/diagnostics14070743.
3
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis.
BMC Gastroenterol. 2022 Jul 26;22(1):355. doi: 10.1186/s12876-022-02428-1.
4
Overview of Complications in Cirrhosis.
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14.
5
CT hepatic arterial perfusion index does not allow stratification of the degree of esophageal varices and bleeding risk in cirrhotic patients in Child-Pugh classes A and B.
Abdom Radiol (NY). 2021 Dec;46(12):5586-5597. doi: 10.1007/s00261-021-03259-6. Epub 2021 Aug 27.
6
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.
Hepatology. 2021 Jun;73(6):2468-2483. doi: 10.1002/hep.31617. Epub 2021 Apr 19.
7
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
Int J Mol Sci. 2020 Aug 28;21(17):6223. doi: 10.3390/ijms21176223.
8
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis.
Aging (Albany NY). 2018 Jun 21;10(6):1424-1441. doi: 10.18632/aging.101478.
9
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury.
Biomed Res Int. 2016;2016:3162670. doi: 10.1155/2016/3162670. Epub 2016 Oct 24.
10
Targeting the renin-angiotensin system in liver fibrosis.
Hepatol Int. 2016 Sep;10(5):730-2. doi: 10.1007/s12072-016-9740-7. Epub 2016 May 31.
本文引用的文献
1
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.
Hepatology. 2011 May;53(5):1629-40. doi: 10.1002/hep.24238.
2
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
J Gastrointestin Liver Dis. 2011 Mar;20(1):77-80.
3
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.
Fibrogenesis Tissue Repair. 2010 Oct 21;3:21. doi: 10.1186/1755-1536-3-21.
4
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
5
Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.
Semin Liver Dis. 2010 Aug;30(3):258-70. doi: 10.1055/s-0030-1255355. Epub 2010 Jul 21.
6
Toll-like receptor 4 and hepatic fibrogenesis.
Semin Liver Dis. 2010 Aug;30(3):232-44. doi: 10.1055/s-0030-1255353. Epub 2010 Jul 21.
7
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells.
J Clin Invest. 2010 Jul;120(7):2379-94. doi: 10.1172/JCI41203. Epub 2010 Jun 23.
8
Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver.
Hepatology. 2010 Aug;52(2):590-601. doi: 10.1002/hep.23739.
9
Carvedilol for portal hypertension in patients with cirrhosis.
Hepatology. 2010 Jun;51(6):2214-8. doi: 10.1002/hep.23689.
10
Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells.
Biochem J. 2010 Mar 15;427(1):29-40. doi: 10.1042/BJ20091512.
Zotero 插件